Expasy logo

UniProtKB/Swiss-Prot variant pages

UniProtKB/Swiss-Prot Q9NVV9: Variant p.Asp17Gly

THAP domain-containing protein 1
Gene: THAP1
Feedback?
Variant information Variant position: help 17 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Type of variant: help LP/P [Disclaimer] The variants are classified into three categories: LP/P, LB/B and US.
  • LP/P: likely pathogenic or pathogenic.
  • LB/B: likely benign or benign.
  • US: uncertain significance
Residue change: help From Aspartate (D) to Glycine (G) at position 17 (D17G, p.Asp17Gly). Indicates the amino acid change of the variant. The one-letter and three-letter codes for amino acids used in UniProtKB/Swiss-Prot are those adopted by the commission on Biochemical Nomenclature of the IUPAC-IUB.
Physico-chemical properties: help Change from medium size and acidic (D) to glycine (G) The physico-chemical property of the reference and variant residues and the change implicated.
BLOSUM score: help -1 The score within a Blosum matrix for the corresponding wild-type to variant amino acid change. The log-odds score measures the logarithm for the ratio of the likelihood of two amino acids appearing by chance. The Blosum62 substitution matrix is used. This substitution matrix contains scores for all possible exchanges of one amino acid with another:
  • Lowest score: -4 (low probability of substitution).
  • Highest score: 11 (high probability of substitution).
More information can be found on the following page
Variant description: help In DYT6. Any additional useful information about the variant.
Other resources: help Links to websites of interest for the variant.


Sequence information Variant position: help 17 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Protein sequence length: help 213 The length of the canonical sequence.
Location on the sequence: help MVQSCSAYGCKNRYDK D KPVSFHKFPLTRPSLCKEWE The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.
Residue conservation: help The multiple alignment of the region surrounding the variant against various orthologous sequences. 
Human                         MVQSCSAYGCKNRYDKDKPVSFHKFPLTRPSLCKEWE

Mouse                         MVQSCSAYGCKNRYDKDKPVSFHKFPLTRPSLCKQWE

Rat                           MVQSCSAYGCKNRYDKDKPVSFHKFPLTRPSLCKQWE

Bovine                        MVQSCSAYGCKNRYDKDKPVSFHKFPLTRPSLCKKWE

Xenopus tropicalis            MVQSCSAYGCKNRYDKDKPISFHKFPLKRPLLCRKWE

Zebrafish                     MVQSCSAYGCKNRYQKDRNISFHKFPLARPEVCVQWV
Sequence annotation in neighborhood: help The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:
  • Type: the type of sequence feature.
  • Positions: endpoints of the sequence feature.
  • Description: contains additional information about the feature.
TypePositionsDescription
Chain 1 – 213 THAP domain-containing protein 1
Zinc finger 1 – 81 THAP-type
Mutagenesis 4 – 4 S -> A. Does not affect DNA-binding.
Mutagenesis 5 – 5 C -> A. Abolishes DNA- and zinc-binding.
Mutagenesis 6 – 6 S -> A. Does not affect DNA-binding.
Mutagenesis 8 – 8 Y -> A. Does not affect DNA-binding.
Mutagenesis 10 – 10 C -> A. Abolishes DNA- and zinc-binding.
Mutagenesis 11 – 11 K -> A. Partially affects DNA-binding.
Mutagenesis 16 – 16 K -> A. Does not affect DNA-binding.
Mutagenesis 24 – 24 K -> A. Strongly affects DNA-binding.
Mutagenesis 26 – 26 P -> A. Abolishes DNA- and zinc-binding.
Mutagenesis 27 – 27 L -> A. Partially affects DNA-binding.
Mutagenesis 28 – 28 T -> A. Does not affect DNA-binding.
Mutagenesis 29 – 29 R -> A. Strongly affects DNA-binding.
Mutagenesis 30 – 30 P -> A. Does not affect DNA-binding.
Mutagenesis 31 – 31 S -> A. Does not affect DNA-binding.
Mutagenesis 32 – 32 L -> A. Does not affect DNA-binding.
Mutagenesis 33 – 33 C -> A. Does not affect DNA-binding.
Mutagenesis 34 – 34 K -> A. Does not affect DNA-binding.
Mutagenesis 35 – 35 E -> A. Does not affect DNA-binding.
Mutagenesis 36 – 36 W -> A. Abolishes DNA- and zinc-binding.
Mutagenesis 37 – 37 E -> A. Partially affects DNA-binding.
Beta strand 16 – 18



Literature citations
Novel THAP1 sequence variants in primary dystonia.
Xiao J.; Zhao Y.; Bastian R.W.; Perlmutter J.S.; Racette B.A.; Tabbal S.D.; Karimi M.; Paniello R.C.; Wszolek Z.K.; Uitti R.J.; Van Gerpen J.A.; Simon D.K.; Tarsy D.; Hedera P.; Truong D.D.; Frei K.P.; Dev Batish S.; Blitzer A.; Pfeiffer R.F.; Gong S.; LeDoux M.S.;
Neurology 74:229-238(2010)
Cited for: VARIANTS DYT6 CYS-9; GLY-17; SER-132; THR-149; THR-166 AND LYS-187; Novel THAP1 gene mutations in patients with primary dystonia from Southwest China.
Song W.; Chen Y.; Huang R.; Chen K.; Pan P.; Yang Y.; Shang H.F.;
J. Neurol. Sci. 309:63-67(2011)
Cited for: VARIANT DYT6 GLY-174; In-depth Characterization of the Homodimerization Domain of the Transcription Factor THAP1 and Dystonia-Causing Mutations Therein.
Richter A.; Hollstein R.; Hebert E.; Vulinovic F.; Eckhold J.; Osmanovic A.; Depping R.; Kaiser F.J.; Lohmann K.;
J. Mol. Neurosci. 62:11-16(2017)
Cited for: SUBUNIT; REGION; VARIANTS DYT6 VAL-143; THR-149; PRO-150; THR-166; GLN-169; ARG-170; GLY-174; PRO-177 AND SER-180; CHARACTERIZATION OF VARIANTS DYT6 THR-149; PRO-150; THR-166; GLN-169; ARG-170; GLY-174; PRO-177 AND SER-180;
Disclaimer: Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. They are not in any way intended to be used as a substitute for professional medical advice, diagnostic, treatment or care.